Ovarian cancer remains a lethal gynecological malignancy, often characterized by late presentation, widespread peritoneal dissemination, and high recurrence rates. While conventional oncology focuses heavily on genomic drivers, recent discoveries highlight metabolic adaptability as a vital pillar of tumor survival. Neoplastic cells in the peritoneal cavity encounter severe microenvironmental stressors, such as profound hypoxia and inadequate nutrient delivery. Consequently, malignant cells undergo lipid metabolic reprogramming, rewiring cellular biochemistry to sustain autonomous growth, counteract oxidative stress, and facilitate metastatic colonization. Understanding these intricate pathways provides essential clinical insights for developing targeted therapeutic strategies against aggressive ovarian tumors.

Molecular Drivers of Fatty Acid Synthesis and Exogenous Uptake

Neoplastic ovarian cells depend on both de novo lipogenesis and exogenous lipid scavenging to sustain rapid membrane biogenesis. Unlike healthy somatic tissues, ovarian carcinomas upregulate critical lipogenic enzymes, including ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FASN). This sustained enzymatic activity converts cytoplasmic carbons into saturated fatty acids. Furthermore, stearoyl-CoA desaturase 1 (SCD1) introduces double bonds into saturated acyl chains, generating monounsaturated fatty acids that prevent lipotoxicity and suppress ferroptosis. In parallel, ovarian cancer cells enhance lipid acquisition through surface receptors, particularly fatty acid translocase (CD36) and low-density lipoprotein receptors (LDLR). Cytoplasmic fatty acid-binding proteins, such as FABP4, then transport these internalized lipids to metabolic organelles. Together, these coordinated pathways ensure an uninterrupted supply of structural lipids and signaling molecules, which shields malignant clones against severe nutrient deprivation.

Mitochondrial Fatty Acid Oxidation and Energetic Adaptation

Beyond membrane generation, ovarian tumors rely on fatty acid oxidation (FAO) for energetic balance and survival during transcoelomic dissemination. Ischemia and glucose deprivation in the peritoneal cavity frequently trigger a metabolic shift toward mitochondrial β-oxidation. Carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme of the carnitine shuttle, mediates the influx of long-chain fatty acids into mitochondria. Elevated CPT1 expression correlates strongly with disease aggressiveness and metastatic progression. Through sequential β-oxidation, acyl-CoA molecules yield abundant acetyl-CoA, fueling the tricarboxylic acid cycle and ATP production. Crucially, this metabolic breakdown also generates reduced nicotinamide adenine dinucleotide phosphate (NADPH), which helps regenerate reduced glutathione. Consequently, ovarian cancer cells effectively neutralize dangerous reactive oxygen species during anchorage-independent transit. By simultaneously providing metabolic energy and antioxidant defense, fatty acid oxidation secures tumor cell viability under severe microenvironmental stress.

The Omental Microenvironment and Adipocyte Crosstalk

The frequent metastasis of ovarian cancer to the omentum illustrates the critical role of host-tumor metabolic interactions. Omental adipocytes serve as active metabolic partners rather than simple structural support. When exfoliated ovarian cancer cells encounter omental tissue, adipocytes undergo lipolysis and release substantial quantities of free fatty acids. Malignant cells upregulate FABP4 at the tumor-adipose interface, facilitating rapid fatty acid absorption. In response, invading tumor cells secrete pro-inflammatory cytokines, including IL-6 and IL-8, which further accelerate adipocyte lipolysis. This bidirectional signaling cascade activates oncogenic pathways such as JAK/STAT3 and PI3K/Akt, accelerating local invasion and proliferation. As surrounding adipocytes delipidate, they release pro-angiogenic factors that construct a supportive pre-metastatic niche. Thus, ovarian cancer cells actively co-opt local adipose tissue, creating a metabolic microenvironment that sustains peritoneal dissemination.

Lipid Metabolic Reprogramming and Chemoresistance Mechanisms

Platinum resistance represents a major clinical barrier in ovarian cancer management, and lipid metabolic reprogramming actively drives this refractory phenotype. Exposure to platinum agents triggers toxic reactive oxygen species and DNA damage, but metabolically reprogrammed cells utilize lipids to resist apoptosis. Overexpression of FASN and SCD1 alters plasma membrane composition, increasing lipid raft abundance and reducing drug permeability. These biophysical adaptations impede intracellular chemotherapeutic accumulation while enhancing ABC transporter activity. Furthermore, ovarian cancer stem cells accumulate intracellular lipid droplets, which serve as protective energy reserves and antioxidant buffers. By sequestering polyunsaturated fatty acids within triglycerides, these droplets prevent lethal lipid peroxidation and suppress ferroptosis. Consequently, altered lipid metabolism equips cancer cells with robust physical and biochemical defenses, directly diminishing the efficacy of conventional cytotoxic therapies.

Emerging Therapeutic Strategies and Metabolic Inhibitors

Targeting critical lipid metabolic enzymes represents a promising avenue for overcoming treatment resistance in ovarian cancer. Inhibitors of FASN, such as TVB-2640 (denifanstat), demonstrate strong preclinical efficacy by depleting cellular lipids and promoting apoptosis. Similarly, blocking CPT1 with etomoxir suppresses fatty acid oxidation, exhausting cellular ATP and resensitizing resistant tumors to carboplatin and paclitaxel. Small-molecule SCD1 inhibitors disrupt fatty acid desaturation, inducing endoplasmic reticulum stress and lethal ferroptosis in malignant clones. Additionally, blocking fatty acid uptake using CD36 neutralizing antibodies or FABP4 inhibitors significantly reduces omental metastasis in preclinical models. Combining these metabolic agents with PARP inhibitors or immunotherapy could provide synergistic clinical benefits. Disrupting lipid utilization starves neoplastic cells while simultaneously remodeling immunosuppressive macrophages within the tumor microenvironment.

Morphological Insights and Biomarkers for Precision Oncology

From a pathological perspective, lipid alterations generate distinctive morphological and biochemical signatures that aid clinical stratification. Spatial lipidomics and mass spectrometry imaging reveal significant lipid heterogeneity across primary tumors and metastatic implants. Histological evaluation shows that high lipid droplet density, detected with Oil Red O staining, correlates with aggressive tumor biology and poor prognosis. Furthermore, circulating lipid biomarkers in ascites and plasma, including lysophosphatidic acid (LPA) and altered sphingolipids, show potential for early recurrence detection. Incorporating these lipidomic markers into diagnostic routines may help clinicians identify patients who could benefit from metabolic-targeted therapies. By integrating morphological evaluation with molecular profiling, precision oncology can better address individual metabolic vulnerabilities in ovarian carcinoma.

Frequently Asked Questions

How does lipid metabolic reprogramming contribute to platinum resistance in ovarian cancer?

Lipid metabolic reprogramming promotes platinum resistance through several complementary mechanisms. Upregulated fatty acid synthesis and desaturation alter plasma membrane fluidity, which diminishes chemotherapy uptake while boosting drug efflux pumps. Additionally, enhanced fatty acid oxidation generates NADPH to neutralize reactive oxygen species. Furthermore, intracellular lipid droplets store excess lipids to prevent lethal lipid peroxidation and ferroptosis, allowing ovarian cancer cells to survive cytotoxic chemotherapy regimens.

Why do ovarian cancer cells preferentially metastasize to the omentum?

Ovarian cancer cells metastasize to the omentum because it provides an abundant lipid reservoir. Invading tumor spheroids secrete cytokines like IL-6 and IL-8, inducing adipocyte lipolysis. Ovarian cancer cells then upregulate transport proteins like FABP4 and CD36 to rapidly import the released fatty acids. This continuous nutrient supply fuels energetic demands, accelerates cellular proliferation, and establishes a supportive microenvironment for extensive peritoneal colonization.

What therapeutic targets within lipid metabolism show the most promise for clinical translation?

Key therapeutic targets include fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1), carnitine palmitoyltransferase 1 (CPT1), and the lipid transporter CD36. Preclinical inhibitors targeting these enzymes impair membrane biogenesis, deplete ATP reserves, and induce ferroptosis. Combining these metabolic agents with standard platinum-based chemotherapy, PARP inhibitors, or immune checkpoint inhibitors demonstrates strong potential for overcoming drug resistance and suppressing omental metastases in clinical settings.

Disclaimer: This content is for informational and educational purposes only, and does not substitute professional medical advice, diagnosis, or treatment. It is intended for healthcare professionals only. Readers must exercise independent clinical judgment and consult official drug labels, treatment protocols, and peer-reviewed literature before making diagnostic or treatment decisions. Relying on this content is at your own risk. The publisher and authors disclaim liability for any adverse outcomes, injury, or damages arising from the application of this information. Refer to the latest local and national guidelines for clinical practice.

References

1. Nakayama N et al. Lipid metabolic reprogramming in ovarian cancer: molecular mechanisms and therapeutic implications. Med Mol Morphol. 2026 Aug 23. doi: 10.1007/s00795-026-00469-z. PMID: 42633601.
2. Chaudhry S, Thomas SN, Simmons GE Jr. Targeting lipid metabolism in the treatment of ovarian cancer. Oncotarget. 2022;13:792-807.
3. Li X, et al. Metabolic Reprogramming Shapes the Progression and Therapeutic Landscape of Ovarian Cancer. Front Oncol. 2025;15:1456321.